Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca ...
Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor ...
Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...
Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or ...
For decades, people diagnosed with CLL or SLL have often faced the reality of long-term or even lifelong cancer treatments, as these slow-growing cancers tend to recur frequently, requiring additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results